Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Antibe Therapeutics Inc. has announced plans to file for creditor protection under the CCAA in response to a ruling requiring a US$24 million payment to Nuance Pharma and to manage a hold on their Phase II trial by the FDA. Concurrently, board members Amal Khouri and Jennifer McNealey have stepped down. The company focuses on developing safer therapies for pain and inflammation, with its leading drug otenaproxesul aimed at providing an alternative to opioids and NSAIDs.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.
